Gainers
- Array Biopharma Inc (NASDAQ: ARRY) rose 23.3 percent to $4.50 in pre-market trading after the company disclosed that its COLUMBUS Phase 3 study of encorafenib plus binimetinib for BRAF-mutant melanoma has met primary endpoint.
- Chemtura Corp (NYSE: CHMT) shares rose 17.3 percent to $33.06 in pre-market trading as LANXESS AG NPV (OTC: LNXSF) announced Sunday, it has signed a contract to acquire the company for $33.50 per share in cash or $2.5 billion.
- GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) rose 12.4 percent to $120.85 in pre-market trading as the company revealed Epidiolex has achieved primary endpoint in treating Lennox-Gastaut syndrome. The positive results came from its randomized, double-blind and placebo-controlled final stage clinical study.
- Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares rose 10.6 percent to $14.00 in pre-market trading after dropping 2.54 percent on Friday.
- Lam Research Corporation (NASDAQ: LRCX) rose 5.9 percent to $97.17 in pre-market trading after declining 0.98 percent on Friday.
- Vistagen Therapeutics Inc (NASDAQ: VTGN) shares rose 4.8 percent to $4.56 in pre-market trading after gaining 3.33 percent on Friday.
- Exelixis, Inc. (NASDAQ: EXEL) rose 3.4 percent to $15.40 in pre-market trading as the company disclosed that it has received a $15 million milestone payment for initiation of Phase 3 study for CS-3150.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Losers
- Pain Therapeutics, Inc. (NASDAQ: PTIE) shares fell 61.5 percent to $1.05 in pre-market trading after the company reported that it has received a complete response letter from the FDA. The FDA determined that REMOXY cannot be approved.
- DURECT Corporation (NASDAQ: DRRX) shares fell 40 percent to $1.02 in pre-market trading after the company reported that its licensee Pain Therapeutics has received a complete response letter from the FDA for REMOXY.
- PJT Partners Inc (NYSE: PJT) shares fell 9.8 percent to $23.66 in pre-market trading after rising 0.81 percent on Friday.
- Sorl Auto Parts, Inc. (NASDAQ: SORL) fell 9.7 percent to $3.36 in pre-market trading after declining 0.53 percent on Friday.
- Cal-Maine Foods Inc (NASDAQ: CALM) fell 7.5 percent to $39.00 in pre-market trading after the company reported a wider-than-expected loss for its first quarter.
- Deutsche Bank AG (USA) (NYSE: DB) shares fell around 5 percent to $12.12 in pre-market trading. According to Bloomberg, Deutsche Bank could be forced to raise capital to help finance a $14 billion fee given by the U.S. Justice Department to settle a probe tied to the bank's residential mortgage-backed securities practices prior to the financial crisis. Specifically, the German bank allegedly misled investors over the quality of subprime mortgage bonds it created and sold prior to the 2008 financial crisis.
- Smith & Wesson Holding Corp (NASDAQ: SWHC) shares fell 4.2 percent to $26.40 in pre-market trading after slipping 0.18 percent on Friday.
- Himax Technologies, Inc. (ADR) (NASDAQ: HIMX) shares fell 4 percent to $10.30 in pre-market trading.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.